The Library
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial
Tools
Tools
Tools
(2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial. Lancet, Vol.373 (No.9676). pp. 1681-1692. doi:10.1016/S0140-6736(09)60740-6 Full text not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1016/S0140-6736(09)60740-6
Abstract
Background Incorporation of a taxane as adjuvant treatment for early breast cancer offers potential for further improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration.
Methods in this multicentre, open-label, phase III, randomised controlled trial, 4162 women (aged >18 years) with node-positive or high-risk node-negative operable early breast cancer were randomly assigned by computer-generated permuted block randomisation to receive FEC (fluorouracil 600 mg/m(2), epirubicin 60 mg/m(2), cyclophosphamide 600 mg/m(2) at 3-weekly intervals) for four cycles followed by docetaxel (100 mg/m(2) at 3-weekly intervals) for four cycles (n=2073) or control (n=2089). For the control regimen, centres chose either FEC for eight cycles (n=1265) or epirubicin (100 mg/m(2) at 3-weekly intervals) for four cycles followed by CMF (cyclophosphamide 600 mg/m(2), methotrexate 40 mg/m(2), and fluorouracil 600 mg/m(2) at 4-weekly intervals) for four cycles (n=824). The primary endpoint was disease-free survival. Analysis was by intention to treat (ITT). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN79718493.
Findings All randomised patients were included in the ITT population. With a median follow-up of 62 months, disease-free survival events were seen in 517 of 2073 patients in the experimental group compared with 539 of 2089 controls (hazard ratio [HR] 0.95, 95% CI 0.85-1.08; p=0.44). 75.6% (95% Cl 73.7-77.5) of patients in the experimental group and 74.3% (72.3-76.2) of controls were alive and disease-free at 5 years. The proportion of patients who reported any acute grade 3 or 4 adverse event was significantly greater in the experimental group than in the control group (p<0.0001); the most frequent events were neutropenia (937 events vs 797 events), leucopenia (507 vs 362), and lethargy (456 vs 272).
Interpretation This study did not show any overall gain from the addition of docetaxel to standard anthracycline chemotherapy. Exploration of predictive biomarker-defined subgroups might have the potential to better target the use of taxane-based therapy.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine | ||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School |
||||
| Journal or Publication Title: | Lancet | ||||
| Publisher: | The Lancet Publishing Group | ||||
| ISSN: | 0140-6736 | ||||
| Official Date: | 16 May 2009 | ||||
| Dates: |
|
||||
| Volume: | Vol.373 | ||||
| Number: | No.9676 | ||||
| Number of Pages: | 12 | ||||
| Page Range: | pp. 1681-1692 | ||||
| DOI: | 10.1016/S0140-6736(09)60740-6 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access | ||||
| Funder: | Cancer Research UK, Sanofi-Aventis, Pfizer, Roche | ||||
| Grant number: | CRUK 01/001 |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
